NCT07185776View on ClinicalTrials.gov

A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

October 31, 2027

Conditions
Lipoprotein Disorder
Interventions
DRUG

HRS-5632 Injection

HRS-5632 injection.

DRUG

HRS-5632 Injection Placebo

HRS-5632 injection placebo.

Trial Locations (2)

710038

RECRUITING

The Second Affiliated Hospital of AFMU, Xi’an

710061

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT07185776 - A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events | Biotech Hunter | Biotech Hunter